Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2011-04-19 | Dr. Rubin holds an M.D. from Cornell University Medical College and has extensive experience in clinical development and pharmaceutical companies. |
| 2012-04-13 | Dr. Rubin holds an M.D. from Cornell University Medical College. We believe that Dr. Rubin’s qualifications to serve on our board include his extensive experience in clinical development as well as his medical, commercial and scientific expertise having held executive-level clinical development positions with Bayer Schering Pharma AG, Schering AG and GlaxoSmithKline plc. |
| 2013-04-16 | Dr. Rubin holds an M.D. from Cornell University Medical College. |
| 2014-04-09 | Dr. Rubin has served as Executive Chairman of Titan Pharmaceuticals, Inc., and held executive-level clinical development positions with Bayer Schering Pharma AG, Schering AG and GlaxoSmithKline plc. |
| 2015-04-15 | Dr. Rubin holds an M.D. from Cornell University Medical College. |
| 2016-04-05 | Dr. Rubin holds an M.D. from Cornell University Medical College. We believe that Dr. Rubin’s qualifications to serve on our board include his extensive experience in clinical development as well as his medical, commercial and scientific expertise. |
| 2017-04-04 | Dr. Rubin holds an M.D. from Cornell University Medical College. We believe that Dr. Rubin’s qualifications to serve on our board include his extensive experience in clinical development as well as his medical, commercial and scientific expertise having held executive-level clinical development positions with Bayer Schering Pharma AG, Schering AG and GlaxoSmithKline plc. |
| 2018-04-03 | Dr. Rubin holds an M.D. from Cornell University Medical College. We believe that Dr. Rubin’s qualifications to serve on our board include his extensive experience in clinical development as well as his medical, commercial and scientific expertise having held executive-level clinical development positions with Bayer Schering Pharma AG, Schering AG and GlaxoSmithKline plc. |
| 2019-04-11 | Dr. Rubin holds an M.D. from Cornell University Medical College. We believe that Dr. Rubin’s qualifications to serve on our board include his extensive experience in clinical development as well as his medical, commercial and scientific expertise having held executive-level clinical development positions with Bayer Schering Pharma AG, Schering AG and GlaxoSmithKline plc. |
| 2020-04-22 | Dr. Rubin holds an M.D. from Cornell University Medical College. We believe that Dr. Rubin’s qualifications to serve on our board include his extensive experience in clinical development as well as his medical, commercial and scientific expertise having held executive-level clinical development positions with Bayer Schering Pharma AG, Schering AG and GlaxoSmithKline plc. |
| 2021-04-14 | Dr. Rubin holds an M.D. from Cornell University Medical College. We believe that Dr. Rubin’s qualifications to serve on our board include his extensive experience in clinical development as well as his medical, commercial and scientific expertise having held executive-level clinical development positions with Bayer Schering Pharma AG, Schering AG and GlaxoSmithKline plc. |
| 2022-04-13 | Dr. Rubin holds an M.D. from Cornell University Medical College. We believe that Dr. Rubin’s qualifications to serve on our board include his extensive experience in clinical development as well as his medical, commercial and scientific expertise having held executive-level clinical development positions with Bayer Schering Pharma AG, Schering AG and GlaxoSmithKline plc. |
| 2023-04-11 | Dr. Rubin holds an M.D. from Cornell University Medical College. |
| 2023-08-18 | Marc Rubin, M.D. |
| 2024-04-10 | Dr. Rubin holds an M.D. from Cornell University Medical College. We believe that Dr. Rubin’s qualifications to serve on our board include his extensive experience in clinical development as well as his medical, commercial and scientific expertise having held executive-level clinical development positions with Bayer Schering Pharma AG, Schering AG and GlaxoSmithKline plc. |
| Filing Date | Source Excerpt |
|---|---|
| 2012-04-20 | Marc Rubin is Executive Chairman of Titan Pharmaceuticals and has held senior roles in global clinical and commercial development. |
| 2013-04-12 | Marc Rubin is Executive Chairman of Titan Pharmaceuticals and has extensive executive leadership and management experience in the pharmaceutical industry. |
| 2014-03-21 | Dr. Rubin was Head of Global Research and Development for Bayer Schering Pharma and held executive roles at GlaxoSmithKline. |
| 2015-04-08 | Marc Rubin, M.D., is Executive Chairman of Titan Pharmaceuticals and has extensive executive leadership experience in the pharmaceutical industry. |
| 2016-11-10 | Marc Rubin, M.D., a director since October 2011 and Chairman of the Board since January 2016, is Executive Chairman of Titan Pharmaceuticals, Inc... Dr. Rubin holds an M.D. from Cornell University Medical College. |
| 2017-11-07 | Marc Rubin, M.D., a director since October 2011 and Chairman of the Board since January 2016, is Executive Chairman of Titan Pharmaceuticals, Inc.... We believe Dr. Rubin’s qualifications to sit on our Board of Directors include his extensive executive leadership and management experience in the pharmaceutical industry. |
| 2018-04-11 | Dr. Rubin is Executive Chairman of Titan Pharmaceuticals and has extensive executive leadership and management experience in the pharmaceutical industry. |
| 2019-10-17 | We believe Dr. Rubin’s qualifications to sit on our Board of Directors include his extensive executive leadership and management experience in the pharmaceutical industry. |
| 2020-10-19 | Dr. Rubin holds an M.D. from Cornell University Medical College and is board certified in internal medicine with subspecialties in medical oncology and infectious diseases. |
| 2021-10-12 | Dr. Rubin’s qualifications include executive leadership in pharmaceutical industry. |
| 2022-10-17 | Dr. Rubin is Executive Chairman of Titan Pharmaceuticals and has extensive executive leadership in pharmaceutical industry. |
| 2023-10-06 | Dr. Rubin’s qualifications to sit on our Board of Directors include his extensive executive leadership and management experience in the pharmaceutical industry. |
| 2024-12-03 | Dr. Rubin is Executive Chairman of Titan Pharmaceuticals... We believe Dr. Rubin’s qualifications include his extensive executive leadership and management experience in the pharmaceutical industry. |
| Filing Date | Source Excerpt |
|---|---|
| 2008-04-03 | Marc Rubin, M.D. has served as our President and Chief Executive since October 2007 and as a director since November 2007. ... President and Chief Executive Officer ... No specific committee memberships or director compensation mentioned for Marc Rubin. |
| 2015-07-20 | Marc Rubin, M.D. Executive Chairman of the Board of Directors. Based on Dr. Rubin's position as the executive chairman, his extensive senior management experience and service on boards of directors in the biotechnology and pharmaceutical industries and his medical background, our Board believes that Dr. Rubin has the appropriate set of skills to serve as a member of the Board. |
| 2016-06-29 | Marc Rubin, M.D. (61) served as our President and Chief Executive from October 2007 until December 2008 and was re-engaged as our Executive Chairman in May 2009. He has served on our Board since November 2007. Based on Dr. Rubins position as the executive chairman, his extensive senior management experience and service on boards of directors in the biotechnology and pharmaceutical industries and his medical background, our Board believes that Dr. Rubin has the appropriate set of skills to serve as a member of the Board. |
| 2017-06-26 | Marc Rubin, M.D. served as our President and Chief Executive from October 2007 until December 2008 and was re-engaged as our Executive Chairman in May 2009. Based on Dr. Rubin’s position as our Executive Chairman, his extensive senior management experience and service on boards of directors in the biotechnology and pharmaceutical industries and his medical background, our Board believes that Dr. Rubin has the appropriate set of skills to serve as a member of the Board. The following table summarizes compensation that our non-employee directors earned during 2016 for services as members of our Board. Marc Rubin, M.D. Executive Chairman 2016 Total Compensation $613,311. |
| 2018-07-02 | Marc Rubin, M.D. served as our president and chief executive from October 2007 until December 2008 and was re-engaged as our executive chairman in May 2009. Based on Dr. Rubin’s position as our executive chairman, his extensive senior management experience and service on boards of directors in the biotechnology and pharmaceutical industries and his medical background, our Board believes that Dr. Rubin has the appropriate set of skills to serve as a member of the Board. |
| 2018-12-20 | By Order of the Board of Directors, Marc Rubin, M.D. Executive Chairman of the Board December 20, 2018 |
| 2019-11-20 | Marc Rubin, M.D. (64) served as our president and chief executive from October 2007 until December 2008 and was re-engaged as our executive chairman in May 2009. ... Based on Dr. Rubin’s position as our executive chairman, his extensive senior management experience and service on boards of directors in the biotechnology and pharmaceutical industries and his medical background, our Board believes that Dr. Rubin has the appropriate set of skills to serve as a member of the Board. |
| 2020-01-31 | By Order of the Board of Directors, Marc Rubin, M.D. Executive Chairman of the Board January 31, 2020 |
| 2020-05-22 | By Order of the Board of Directors, Marc Rubin, M.D. Executive Chairman of the Board May 22, 2020 |
| 2020-11-02 | By Order of the Board of Directors, Marc Rubin, M.D. Executive Chairman of the Board November 2, 2020 |
| 2020-11-25 | Marc Rubin, M.D. (65) served as our president and chief executive from October 2007 until December 2008 and was re-engaged as our executive chairman in May 2009. Based on Dr. Rubin’s position as our executive chairman, his extensive senior management experience and service on boards of directors in the biotechnology and pharmaceutical industries and his medical background, our Board believes that Dr. Rubin has the appropriate set of skills to serve as a member of the Board. |
| 2021-11-05 | Marc Rubin, M.D. (66) served as our president and chief executive from October 2007 until December 2008 and was re-engaged as our executive chairman in May 2009. ... Based on Dr. Rubin’s position as our executive chairman, his extensive senior management experience and service on boards of directors in the biotechnology and pharmaceutical industries and his medical background, our Board believes that Dr. Rubin has the appropriate set of skills to serve as a member of the Board. |
| 2023-05-19 | Marc Rubin, M.D. served as Executive Chairman and Director... Marc Rubin 2022 compensation total $426,248. |
Data sourced from SEC filings. Last updated: 2026-02-03